argenx SE
Hieronder vindt u informatie uit het register openbaarmaking voorwetenschap. Deze informatie is door de organisatie verstrekt.
Publicatie datum
13 mrt 2015 - 07:25
Statutaire naam
argenx SE
Titel
arGEN-X to Present at 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference
Bericht
Breda, the Netherlands / Ghent, Belgium, 13 March 2015 - arGEN-X N.V. (Euronext Brussels: ARGX), a clinical-stage biopharmaceutical company focused on creating and developing differentiated therapeutic antibodies for the treatment of cancer and severe autoimmune diseases, today announced that Chief Scientific Officer, Prof. Hans de Haard, Ph.D., will present a corporate update at the 22nd Annual BioCentury Future Leaders in the Biotech Industry Conference in New York City (NY, USA) on Friday, 20 March 2015 at 9:30am ET.
Gerelateerde downloads
Datum laatste update: 22 december 2025